Introduction
There are currently no approved or widely effective medications to curb addiction to psychostimulant drugs like cocaine. Manipulations targeting muscarinic cholinergic systems can modulate abuse-related effects of cocaine, and muscarinic receptors are thus emerging as potential targets for medications development in cocaine addiction [1] . We have previously shown that agonists or positive allosteric modulators that selectively stimulate either the M 1 or the M 4 muscarinic receptor subtypes attenuate the discriminative stimulus (S D ) 2 effects and reinforcing effects of cocaine in rats and mice ( [2] [3] [4] [5] 6] mediate the rate-suppressing side effects that were observed with less selective ligands [2, 5] . Conversely, muscarinic receptor antagonists increased the S D effect of cocaine, and can produce cocaine-appropriate responding when substituted for cocaine [2, [7] [8] [9] . Based on rat studies that used intracranial infusions or lesions, striatal areas appear to be central to mediating both the S D effects of cocaine [10, 11] , and the modulation of cocaine's effects by muscarinic receptor ligands [12] [13] [14] [15] . Striatal tissues express predominantly the M 1 and M 4 muscarinic receptor subtypes, and lower densities of the M 2 subtype: M 1 receptors mostly postsynaptically, M 4 receptors both preand postsynaptically, and M 2 receptors mostly as presynaptic inhibitory autoreceptors [16] [17] [18] [19] [20] . M 2 and M 4 receptors modulate the tonic acetylcholine release by striatal cholinergic interneurons, which in turn modulates striatal dopamine release via a nicotinic receptor-dependent mechanism [21] [22] [23] [24] [25] . Postsynaptically, M 1 and M 4 receptors modulate the excitability and activity patterns of GABAergic medium spiny neurons, the striatum's main output neurons. M 1 and M 4 receptor activation has long been known to produce functional dopamine antagonism, but more recent studies are showing the reciprocal modulation of striatal dopamine and acetylcholine release to be quite complex (for review, see [26] [27] [28] [29] ). Here, we used subtype-preferring muscarinic receptor antagonists and knockout mice lacking M 1 , M 2 , or M 4 receptors to investigate the contributions of specific muscarinic receptor subtypes in the muscarinic/cocaine interaction in the drug discrimination assay. Scopolamine is a non-selective muscarinic antagonist with comparable affinities at the M 1 and M 3 -M 5 subtypes and a marginally lower affinity at the M 2 subtype [30] [31] [32] . Telenzepine is a moderately M 1 -preferring antagonist, and trihexyphenidyl has about equal affinity at M 1 and M 4 receptors, with modest selectivity over M 2 , M 3 , and M 5 subtypes [30, 33, 34] . Tropicamide was reported to be a modestly M 4 -preferring antagonist with comparable affinities across M 1 -M 3 subtypes [35] . Methoctramine and AQ-RA 741 are M 2 -preferring antagonists, with methoctramine generally showing a more selective profile than AQ-RA 741 [33, [36] [37] [38] [39] . Methoctramine binds at both the orthosteric site and an allosteric site on M 2 receptors, but the latter only at high concentrations less likely to be relevant in vivo [40, 41] . Each antagonist was either shown to be fully brain penetrant, or has been inferred to penetrate the central nervous system based on producing effects known to be centrally mediated, following systemic administration [32, [42] [43] [44] .
Materials and methods

Animals
Male Swiss-Webster, C57BL/6NTac, M 
Training and evaluation in cocaine discrimination
Operant-conditioning chambers and the experimental procedure were as previously described [2] . In brief, each chamber contained two nose-poke holes each equipped with a photocell and a cue light, and a cup into which liquid food was delivered from a syringe pump. Mice were trained to discriminate 10 mg/kg cocaine from saline (i.p.), reinforced with Vanilla-flavored Ensure nutrition drink. 30 reinforcers were available per 20-min session. Mice were trained initially under a FR 1 schedule, then, the ratio was gradually increased to FR 10, with increasing pretreatment time spent in the chamber rather than home cage. Eventually, sessions were preceded by the 10-min pretreatment period in the chamber, during which all lights were off, and responding had no scheduled consequences. Cocaine and saline were presented in pseudorandom order across daily training sessions, typically five days/ week, and mice were counterbalanced with cocaine trained on the left or right nose-poke. Stable discrimination was defined as at least 7 of 8 consecutive sessions satisfying the following criteria: 1) ≥10 reinforcers earned per session, 2) ≥80% correct responses for the first reinforcer, and 3) ≥90% correct total responses.
Once criteria were met, mice were tested with saline, 0.32, 1.0, 3.2, 10, and 18 mg/kg cocaine to generate dose-effect functions. The non subtype-selective antagonist scopolamine (0.032-10 mg/kg i.p.), the M 1 /M 4 -preferring antagonists telenzepine (3.2-56 mg/kg s.c.) and trihexyphenidyl (0.032-32 mg/kg i.p.), the M 4 -preferring antagonist tropicamide (0.1-10 mg/kg s.c.), and the M 2 -preferring antagonists AQ-RA 741 and methoctramine (0.1-3.2 mg/kg s.c.) were each tested alone (i.e., as "substitution" for cocaine stimulus). In addition, pretreatment/combination tests were conducted, in which cocaine doses were tested in combination with scopolamine (0.32 mg/kg i.p., administered with cocaine as a single injection), tropicamide (0.1 mg/ kg s.c.), AQ-RA 741 (0.1-1 mg/kg s.c.), and methoctramine (0.0032-1.0 mg/kg s.c.). Pretreatment times before cocaine injection (when tested in combination) or before session start (when tested alone as substitution) were: telenzepine, 10 min; methoctramine, 15 min; all other drugs, immediately before. Doses were tested within-subjects in a counterbalanced sequence. At least one training session was interspersed between each test session, and tests were only performed when mice satisfied discrimination criteria. If responding was suppressed to less than 10 responses in a session, the quantity of behavior was considered insufficient to evaluate response selection and the percentage of drug-appropriate responding (DAR) was not included in the data set.
Drugs
Cocaine hydrochloride was supplied by the National Institute on Drug Abuse (National Institutes of Health, Bethesda, MD), Scopolamine hydrobromide, telenzepine dihydrochloride hydrate, trihexyphenidyl hydrochloride, tropicamide, and methoctramine hydrate were purchased from Sigma-Aldrich (St. Louis, MO). AQ-RA 741 was purchased from R & D Systems, Inc (formerly Tocris, Ellisville, MO). Cocaine, scopolamine, telenzepine, and AQ-RA 741 were dissolved in 0.9% saline, methoctramine, in sterile water. Trihexyphenidyl was dissolved by gentle heating in sterile water. Tropicamide was dissolved in ethanol and diluted to ≤1% ethanol in sterile water. All drug doses refer to the weights of the respective salts. Vehicles, route of administration, pretreatment times, and initial dose ranges were selected based on published reports, and adjusted empirically in initial studies [2, 44, [48] [49] [50] [51] .
Data analysis
The %DAR for the whole session and total rates of responding (i.e., in both holes) are presented. Comparable effects were observed in % DAR for the first reinforcer, unless stated otherwise. Repeated measures ANOVA were performed with dose of pretreatment drug and/or cocaine or dose of substitution drug, as variables, on %DAR and response rate. For knockout strain studies, ANOVA were performed with genotype as between-subjects variable and drug doses/pretreatments as repeatedmeasures variables. Occasionally, responding was eliminated or suppressed to the point that no reinforcers were earned during the session; in those cases, no %DAR was calculated for that mouse (i.e., missing value). Data are reported as group means with standard error of the mean. Significance level was set at P < 0.05; statistical software was Stata/SE for Mac.
Results
"Cocaine-like" muscarinic receptor antagonists in Swiss-Webster mice
In outbred Swiss-Webster mice, the M 1 /M 4 -preferring antagonists telenzepine and trihexyphenidyl, and the M 4 -preferring antagonist tropicamide, each produced some cocaine-appropriate responding, with peak averages between 38% and 61% ( Fig. 1) . DAR was related to antagonist dose for telenzepine [F(3,21) = 4.07, P < 0.05], trihexyphenidyl [F(3,39) = 3.68, P < 0.05], and tropicamide [F(5,39) = 3.82, P < 0.01]. Trihexyphenidyl decreased rates of responding at the highest dose tested (main effect [F(3,39) = 14.3, P < 0.0001]; 32 mg/kg vs. vehicle P < 0.001). Tropicamide and telenzepine did not affect rates of responding significantly.
When telenzepine (3.2 mg/kg) and tropicamide (0.1 mg/kg) were tested in combination with cocaine, each antagonist produced a small shift of the cocaine dose-effect function to the left (Fig. 2) , but only the effect of tropicamide reached statistical significance by ANOVA [F (1,63) = 10.6, P < 0.01]. The effect of cocaine dose on response allocation was always highly significant (P < 0.0001). In two mice, telenzepine profoundly suppressed responding at the highest doses (despite no to minimal effects on rates of responding in other mice), which resulted in missing values and consequently reduced statistical power. As an alternative analysis method less affected by missing values, potencies of cocaine were calculated by interpolation in each mouse with and without telenzepine, which confirmed a leftward shift (1.34 mg/kg, 95% confidence interval 0.68-2.65 vs. 0.39 [0.23-0.65] mg/kg, P < 0.01 by paired-sample t-test). Telenzepine produced a small decrease in rates of responding regardless of the cocaine dose [F (1,62) = 6.90, P < 0.05], while tropicamide did not affect rates. A low dose of scopolamine can shift the cocaine discrimination dose-effect function to the left in intact mice [2] . To test the hypothesis that M 1 receptors also mediated the potentiation of the cocaine discriminative stimulus effect by scopolamine, we determined cocaine dose-effect functions with and without 0. (Fig. 4) . A three-way ANOVA with the factors genotype, cocaine, and scopolamine confirmed a significant genotype by scopolamine interaction [F(3,237) = 6.11, P < 0.0001], and follow-up simple effects confirmed a significant effect of scopolamine in each knockout line (P < 0.05 to P < 0.001). No evidence of toxicity was observed in the M 2 −/− mice with this dosing. The effect of cocaine dose on DAR was significant in all pretreatment/combinations tests (P < 0.0001).
"Cocaine-attenuating" muscarinic receptor antagonists in SwissWebster mice
The M 2 -preferring antagonist methoctramine produced little cocaine-appropriate responding per se, with a maximal DAR of 35% at the highest dose (main effect [F(4,26) = 3.43, P < 0.05]; 3.2 mg/kg vs. vehicle P < 0.05), (Fig. 5A ). Methoctramine was tested over a range of doses, up to doses that produced rate-decreasing effects [F(4,28) = 7.21, < 0.001].
We then tested methoctramine in combination with cocaine, testing for a shift in the cocaine dose-effect function at two doses of methoctramine, and testing a range of methoctramine doses in combination with 3.2 mg/kg cocaine. As opposed to scopolamine and the M 1 / M 4 receptor-preferring antagonists telenzepine, trihexyphenidyl, and tropicamide, methoctramine moderately attenuated the cocaine discriminative stimulus effect in Swiss-Webster mice: administration of 0.01 mg/kg methoctramine produced a small shift of the dose-effect function to the right ( Fig. 5B; methoctramine effect [F(1,53) = 4.34, P < 0.05], cocaine by methoctramine interaction [F(4,53) = 2.67, P < 0.05]. At 1.0 mg/kg, methoctramine had no signignificant effect on DAR (in fact showed a trend to shift the cocaine curve to the left), and moderately decreased rates of responding ([F(1,63) = 17.6, P = 0.0001; Fig. 5C ). This "biphasic" effect was also apparent when testing a range of methoctramine doses with 3.2 mg/kg cocaine, in which doses from 0.01 to 0.32 mg/kg methoctramine decreased DAR (main effect of methoctramine dose [F(6,30) = 3.28, P < 0.05]), but 1 mg/kg had no effect (Fig. 5D) .
In an effort to replicate those findings, the putative M 2 -preferring antagonist AQ-RA 741 was also tested. AQ-RA 741 alone produced no cocaine-appropriate responding in a range of doses previously shown to be active in vivo (no effect of dose on DAR or rate; see Supplemental Fig. 2A) . However, the selectivity of AQ-RA 741 is modest, and the usefulness of those data is limited by the fact that higher, ratesuppressing doses were not tested, out of concerns for potential toxicity. Administration of 1.0 mg/kg AQ-RA 741 produced a small shift of the cocaine dose-effect function to the right (Supplemental Fig. 2B ), although the effect only reached statistical significance for the first reinforcer (AQ-RA 741 dose [F(1,62) = 4.45, P < 0.05], AQ-RA 741 by cocaine interaction [F(4,62) = 2.98, P < 0.05]), but not for totalsession responding. A range of AQ-RA 741 doses were tested with 3.2 mg/kg cocaine (Supplemental Fig. 2C ). Again, AQ-RA 741 produced moderate decreases in DAR that was significant for first-reinforcer responding [F(3,15) = 4.43, P < 0.05] (total session analysis: P = 0.06). Rates of responding were not significantly affected.
"Cocaine-attenuating" muscarinic receptor antagonists in muscarinic receptor knockout mice
Because methoctramine has relatively low selectivity for the M 2 subtype, we wanted to test the hypothesis that effects on cocaine discrimination were mediated through M 2 receptors. To this end, we tested 0.032 mg/kg methoctramine as pretreatment to cocaine in wildtype mice, M 1 −/− mice, M 2 −/− mice, and M 4 −/− mice (Fig. 6) . A three-way ANOVA with the factors genotype, cocaine dose and methoctramine dose confirmed a significant genotype by methoctramine interaction [F(3,205) = 2.97, P < 0.05]. As hypothesized, methoctramine had no effect in the M 2 −/− mice (Fig. 6C) , while the moderate rightward shift observed in the Swiss-Webster mice was confirmed in the wild-type mice (P = 0.001; Fig. 6A ). The effect appeared intact in the M 4 −/− mice (P < 0.01; Fig. 6D ), but was diminished in the M 1 −/− mice, in which the shift was not significant (Fig. 6B ).
Discussion
Muscarinic receptor antagonists can partially mimic and increase the S D effects of cocaine, but the muscarinic receptor subtypes involved in these effects are not known. We tested muscarinic receptor antagonists with no subtype selectivity, or moderately preferential affinity at the 
Cocaine-like effects of non-selective and M 1 /M 4 -preferring antagonists in intact mice
We previously showed that scopolamine produced cocaine-appropriate responding in Swiss-Webster mice (partial substitution with an inverted U-shaped curved), and that a sub-threshold dose of scopolamine shifted the cocaine dose-effect curve to the left [2] . Methylscopolamine, which has poor brain penetration, was less potent than scopolamine in producing these effects, indicating a centrally mediated effect [2] . This is in agreement with earlier studies in rats, in which the non subtype-selective muscarinic antagonists atropine and scopolamine produced leftward shifts in cocaine's S D effects [7, 8] . Potentiation of psychostimulant effects by muscarinic receptor blockade has been observed consistently in mice, rats, and non-human primates across a range of endpoints, including locomotor activity, stereotypies, and intravenous self-administration [8, [52] [53] [54] [55] . Isobolographic analyses confirmed that the effects of cocaine-scopolamine combinations were more than additive both in drug discrimination in mice, and in locomotor activity in rats, implying that muscarinic receptor antagonists and cocaine produce their effects through different brain pathways [2, 56] . The interaction likely involves dopamine release, as systemic administration of muscarinic antagonists induces striatal dopamine release in humans and rats, and potentiates cocaine-induced dopamine increases [34, 57, 58] .
Here, M 1 and/or M 4 -preferring antagonists produced some cocaineappropriate responding, comparable to results obtained previously with scopolamine [2] . Previous investigations similarly found that the moderately M 1 -preferring antagonists telenzepine and trihexyphenidyl potentiated the locomotor stimulant and/or S D effects of cocaine in rats [9, 34] . Tropicamide was described as somewhat M 4 -preferring, although recent data suggest that it is a relatively nonspecific muscarinic antagonist [35, 59] . Effects of M 4 receptor blockade on cocaine's S D effects have not been reported previously, but our findings are consistent with a report that tropicamide increased or prolonged cocaine-induced stereotypies in rats [52] . The notion that blocking either M 1 receptors or M 4 receptors increases effects of cocaine is also consistent with our findings that, conversely, pharmacological stimulation of M 1 and/or M 4 receptors attenuated the S D effects and reinforcing effects of cocaine in rats and mice ( [2] [3] [4] [5] 6] ). Taken together, this first data set suggests that M 1 and/or M 4 receptor blockade at least partly mediate the effects of scopolamine in the cocaine discrimination assay.
Cocaine-like effects of muscarinic antagonists in muscarinic receptor knockout mice
Brain-penetrant muscarinic receptor antagonists with a high degree of selectivity for each of the five receptor subtypes are still being developed, and we therefore used a combination of subtype-preferring ligands and receptor knockout mice to determine the contributions of individual receptor subtypes to the above effects. Cocaine produced comparable S D dose-effect functions in all four strains − wild-type,
, and M 4 −/− . In contrast, substitution of scopolamine for cocaine revealed striking differences: scopolamine produced over 80% cocaine-appropriate responding in the wild-type mice, but no appreciable cocaine-appropriate responding in the M 1 −/− mice in the same dose range. Partial substitution was observed in the M 4 −/− mice.
Although we cannot exclude that higher doses of scopolamine could have produced some cocaine-appropriate responding in the knockout mice, these findings indicate that M 1 receptors are necessary for scopolamine to produce cocaine-S D like effects, while M 4 receptors may contribute partially to the effect. When we tested scopolamine in combination with cocaine, the M 1 −/− mice again showed a qualitatively different effect: whereas scopolamine produced leftward shifts in the cocaine dose-effect func- [6] . It is possible that effects at M 5 receptors play a role as well [66, 67] .
showed plasma levels of scopolamine roughly twice as high as the wildtype controls 30 min after an intraperitoneal injection of 1 mg/kg, as well as a trend for higher brain levels [32] . However, given that scopolamine produced cocaine-like effects up to at least 10 mg/kg in wild-type mice, it seems unlikely that this slightly higher blood level would account for the complete reversal of effect observed here between the wild-type mice and the M 1 −/− mice. 
Cocaine-attenuating effects of M 2 -preferring antagonists
In contrast to the M 1 /M 4 receptors, we did not anticipate that blockade of the (primarily presynaptic) M 2 receptors would produce cocaine-like effects in the drug discrimination assay. Indeed, neither methoctramine nor AQ-RA 741 substituted for cocaine in intact mice, with the caveat that neither ligand is highly selective for the M 2 receptor, and that neither ligand was tested at doses that produced strong behavioral suppression, due to expected risks of toxicity. To evaluate the effects of methoctramine in combination with cocaine, we therefore tested a wide range of doses (two and a half log units), including doses that may bind M 2 receptors preferentially, and doses that may have off-target effects. This produced a biphasic dose-effect function, from an ineffective, sub-threshold dose, over a range of doses that decreased cocaine-appropriate responding, to a complete reversal of effect this at the highest dose. A biphasic dose-effect function of methoctramine has been observed previously, similarly attributed to recruitment of non-M 2 receptors [60] . M 2 receptor antagonists reduced the S D effects of 3.2 mg/kg cocaine by up to 50% in Swiss-Webster mice, an effect similar to that produced by M 1 /M 4 agonists [2, 5] . When tested against a range of cocaine doses, a small rightward shift was obtained. Brain M 2 receptors are mainly inhibitory autoreceptors [61, 62] . M 2 receptors serve as autoreceptors throughout the brain with the probable exception of the nucleus accumbens, while M 4 receptors appear to serve this function only in the striatum [18, 21, 23, 25] . Consistent with this function, in vitro and in vivo studies have shown that M 2 -preferring antagonists increase acetylcholine in dorsal striatum, hippocampus, and cortex [39, 60, [63] [64] [65] . We therefore hypothesize that the M 2 antagonists attenuated the cocaine S D effect indirectly, through stimulation of brain M 1 and/or M 4 receptors by endogenous acetylcholine. Nicotinic receptors, which also modulate dopamine release in the dorsal and ventral striatum, could also be involved [23] . A complete lack of effect of methoctramine in the M 2 −/− mice supports the interpretation that methoctramine attenuated the cocaine S D effect in intact mice via antagonism of M 2 receptors. Although rat studies indicated that the nucleus accumbens is important in mediating the S D effects of cocaine [10, 11] , the above results suggest that the effect of methoctramine is likely mediated at least partially in dorsal striatum (and/or other brain regions) rather than the nucleus accumbens, because M 4 receptors, not M 2 receptors, serve as autoreceptors in the accumbens [23] . While methoctramine produced a rightward shift of the cocaine curve in wildtype mice and in the M 4 −/− mice, the effect was strongly attenuated in 
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